Illinois Urogynecology, Ltd, Oak Lawn, Illinois 60453-2345, USA.
Neurourol Urodyn. 2010 Nov;29(8):1424-8. doi: 10.1002/nau.20875.
To evaluate 18-month safety and durability of efficacy of nonsurgical transurethral collagen denaturation as treatment for stress urinary incontinence (SUI) in women.
Study comprised women with SUI due to bladder outlet hypermobility for at least 12 months who failed conservative treatment and had not undergone surgery or bulking agent treatment. This one-time procedure was performed in a physician's office or ambulatory treatment center. Patients kept voiding diaries and completed the Incontinence Quality of Life (I-QOL), Urogenital Distress Inventory (UDI-6), and Patient Global Impression of Improvement measures at baseline and at 3, 6, 12, and 18 months posttreatment.
At 18 months, intent-to-treat analysis revealed that patients experienced significant reductions in the median number of stress leaks daily (0.43; P < 0.006) and weekly (3.0; P < 0.006) versus baseline, with 46.7% reporting a 50% or greater reduction in leakage. Mean I-QOL score improved 10.9 points (median 8.5; P < 0.0001), with 47.8% having a 10-point or greater improvement and 50.4% reporting improved symptoms versus baseline. Mean UDI-6 improvement was 13.0 points, with a stress incontinence subscore improvement of 17.0 points. Overall, 47.0% of patients were "somewhat" or "very" satisfied, and 52.9% would recommend the procedure to a friend. The procedure was shown to be safe and effective, with no new treatment-related adverse events reported at 18 months.
Transurethral collagen denaturation resulted in significant improvements in stress leaks and quality of life for at least 18 months. This procedure offers a safe, effective, nonsurgical treatment option for women with SUI.
评估非手术经尿道胶原蛋白变性治疗女性压力性尿失禁(SUI)的 18 个月安全性和疗效持久性。
本研究纳入了至少 12 个月因膀胱出口过度活动导致 SUI 且经保守治疗失败、且未接受过手术或填充剂治疗的女性。该一次性治疗在医生办公室或日间治疗中心进行。患者保留排尿日记,并在基线及治疗后 3、6、12 和 18 个月时完成尿失禁生活质量(I-QOL)、尿生殖窘迫量表(UDI-6)和患者整体改善印象评分。
在 18 个月时,意向治疗分析显示患者每日(0.43;P<0.006)和每周(3.0;P<0.006)压力性漏尿中位数显著减少,46.7%的患者报告漏尿减少 50%或更多。I-QOL 评分平均改善 10.9 分(中位数 8.5;P<0.0001),47.8%的患者改善 10 分或更多,50.4%的患者报告症状较基线改善。UDI-6 平均改善 13.0 分,压力性尿失禁亚评分改善 17.0 分。总体而言,47.0%的患者“有些”或“非常”满意,52.9%的患者会向朋友推荐该治疗。该治疗在 18 个月时显示安全有效,无新的与治疗相关的不良事件报告。
经尿道胶原蛋白变性治疗可显著改善压力性漏尿和生活质量至少 18 个月。该治疗为 SUI 女性提供了一种安全、有效、非手术的治疗选择。